Herantis Pharma on inderesTV December 11th -December 08, 2023 at 0101 am EST - Marketscreener.com
| HRTIS Stock | EUR 1.49 0.07 4.49% |
Under 61% of Herantis Pharma's investor base is looking to short. The analysis of current outlook of investing in Herantis Pharma Oyj suggests that many traders are alarmed regarding Herantis Pharma's prospects. Herantis Pharma's investing sentiment shows overall attitude of investors towards Herantis Pharma Oyj.
Herantis |
Herantis Pharma on inderesTV December 11th -December 08, 2023 at 0101 am EST Marketscreener.com
Read at news.google.com
 |
Herantis Pharma Fundamental Analysis
We analyze Herantis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Herantis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Herantis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Herantis Pharma is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Herantis Pharma Oyj Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Herantis Pharma stock to make a market-neutral strategy. Peer analysis of Herantis Pharma could also be used in its relative valuation, which is a method of valuing Herantis Pharma by comparing valuation metrics with similar companies.
Peers
Herantis Pharma Related Equities
| KAMUX | Kamux Suomi | 5.20 | ||||
| NANOFH | Nanoform Finland | 3.25 | ||||
| TOKMAN | Tokmanni Group | 0.00 | ||||
| NXTMH | Nexstim Oyj | 2.63 |
Complementary Tools for Herantis Stock analysis
When running Herantis Pharma's price analysis, check to measure Herantis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Herantis Pharma is operating at the current time. Most of Herantis Pharma's value examination focuses on studying past and present price action to predict the probability of Herantis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Herantis Pharma's price. Additionally, you may evaluate how the addition of Herantis Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |